课题基金 / 基金详情

SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF AND RHU IL4 TO TREAT CANCER

SAFETY AND BIOLOGIC ACTIVITY OF RHU GM-CSF AND RHU IL4 TO TREAT CANCER
RHU GM-CSF 和 RHU IL4 治疗癌症的安全性和生物活性
批准号：
6118445
负责人：
ROBERT Alan FIGLIN
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118445
关键词：
antigen presenting cell clinical research clinical trial phase I colony stimulating factor cytotoxic T lymphocyte drug screening /evaluation human subject human therapy evaluation immune system neoplasm /cancer immunotherapy neoplastic cell tumor antigens

项目摘要

项目成果

ROBERT Alan FIGLIN的其他基金

相似基金

相关文献

中文摘要
翻译
人类的免疫系统在适当的刺激下，具有识别和摧毁癌细胞的能力。虽然肿瘤杀伤的途径很多，但最有效的途径是由肿瘤特异性细胞毒性T淋巴细胞(CTL，1)介导的途径。这些CTL的产生需要许多基本成分，包括肿瘤抗原、特异性抗原提呈细胞(APC)和肿瘤反应性T细胞(2)。该方案的重点是给癌症患者注射重组人GM-CSF和IL-4，作为一种在体内扩增和激活抗原提呈树突状细胞(DC)的手段。
英文摘要
The human immune system, when appropriately stimulated, has the capacity to recognize and destroy cancer cells. While many pathways of tumor killing have been identified, the most potent is that mediated by tumor-specific cytotoxic T-lymphocytes (CTL,1). The generation of these CTL requires a number of essential components including the presence of tumor antigens, specialized antigen presenting cells (APC) and tumor-reactive T cells (2). This protocol focuses on the administration of recombinant human GM-CSF and IL-4 to cancer patients as a means to expand and activate in vivo antigen-presenting dendritic cells (DC).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Late Stage Lung Cancer
Cancer Center Support Grant
Phase II Trial of Recombinant Human Granulocyte Macrop
CORE--CLINICAL RESEARCH UNIT
海外基金